What We Know About Long Covid

The transcript discusses the speaker's personal experience with Lyme disease and its long-term effects, drawing parallels to the emerging chronic condition of long COVID. It highlights the symptoms and challenges faced by long COVID patients, known as long haulers, and the efforts of Bio Incept, a biotech company focused on treating autoimmune diseases and promoting tissue regeneration. The speaker, who transitioned from a banking career to biotech, outlines Bio Incept's plans for a public listing and a study on long COVID, emphasizing the potential impact on patients and the healthcare system.

What is the focus of Bio Incept as mentioned in the text?

What unique opportunity did the speaker see in transitioning to Bio Incept?

What potential does the speaker see for Bio Incept in the near future?